FibroScan 502 Touch-CAP

The ServiDigest Medical/Surgical Centre has a Digestive System Medical-Surgical Department with a Hepatology Unit that specializes in the prevention, study, and treatment of hepatic diseases.

What is the FibroScan CAP®?

Transition Elastography (FibroScan CAP®) is an advanced technique which can quantify the elasticity of the liver, which is a reflection of its degree of rigidity or hepatic fibrosis.

It is a non-invasive, painless, and reproducible method that provides information useful for making short or long term decisions regarding treatment, monitoring, or prognosis of a specific hepatic disease.

It evaluates a tissue volume 100 times greater than hepatic biopsy. Because it does not present any complications, the FibroScan CAP® may be repeated in order to monitor hepatic diseases.

CAP stands for coefficient attenuated parameter. It is performed at the same time as the Transition Elastography and serves to quantify the percentage of fatty infiltration in the liver (Hepatic steatosis).

How is the FibroScan test performed? Preparation

The patient will have fasted and abstained from smoking for at least 3 hours prior to exploration.

The patient will be asked to lie face up on a stretched with his/her right hand under his/her head. A probe, which may be or standard (M) or large-overweight (XL) depending on the characteristics of each patient, will be placed on the lower right hand side of the patient’s thorax. These probes have an ultrasound attached to their tips. These ultrasounds measure the propagation speed of the elastic wave previously produced by a mechanical pulse. This pulse will be felt as a slight pressure on the skin that does not produce any pain.

The patient’s doctor will check the results of the measurements on a screen and will evaluate whether the test is valid.

Are there any contraindications for performing this test?

The FibroScan CAP® is contraindicated for pregnant women and other patients who wear pacemakers and/or cardiac defibrillators, or other active implanted devices, and in the case of having ascites (liquid in the abdominal cavity), which could prevent the test from achieving valid measurements.

Can this test incur any posterior secondary effects?

The FibroScan CAP® does not produce any radiation, nor can it produce any secondary effects.

When should a FibroScan CAP® be indicated?

The FibroScan CAP® is indicated for the study and quantification of the degree of fibrosis and fatty infiltration of the following hepatic diseases:

  • Chronic Hepatitis C (VHC)
  • Chronic Hepatitis B (VHB)
  • Alcoholic Hepatic Disease / Alcoholic Hepatic Steatosis (EHA)
  • Non-Alcoholic Hepatic Disease (EHNA)
  • Autoimmune Hepatitis (HAI)
  • Biliary diseases:
  • Primary Biliary Cirrhosis (PBC)
  • Primary Sclerosing Cholangitis (PSC)

Where can I have a FibroScan CAP® done?

The ServiDigest Medical/Surgical Centre has a FibroScan CAP Service with the most advanced 502 Touch-CAP technology that incorporates two kinds of M and XL probes for performing these specialized studies of the hepatic diseases.